Analyst cuts target to CNY 57.00 for Yunnan Baiyao stock

Published on 10/19/2026 at 01:16 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Yunnan Baiyao reports CNY 21.88 billion in first-half revenue, up 3.00 percent year over year. Twelve analysts give Yunnan Baiyao stock a Buy consensus.

Growth and valuation markers

Futunn reported a target cut from CNY 65.78 to CNY 57.00 on September 23, 2026.
First-half 2026 revenue reached CNY 21.88 billion, up 3.00 percent year over year.
Yunnan Baiyao carried a CNY 94.7 billion market capitalization and a CNY 46.29 to CNY 58.20 52-week range on October 16, 2026.

Yunnan Baiyao, CNE0000008X7, Illustration mit AI erstellt.

Yunnan Baiyao (CNE0000008X7) had its reported analyst target cut from CNY 65.78 to CNY 57.00 on September 23, 2026, while the rating stayed Buy, according to Futunn. The change came after the company reported mixed first-half and second-quarter figures.

Results show uneven momentum

Futunn reported first-half 2026 revenue of CNY 21.88 billion, up 3.00 percent year over year, and net profit attributable to shareholders of CNY 3.70 billion, up 1.90 percent. In the second quarter, revenue was CNY 10.28 billion, down 1.30 percent year over year, while net profit attributable to shareholders reached CNY 1.66 billion, down 2.00 percent.

The comparison improves after one-off investment effects are excluded. Adjusted for special gains and losses linked to investment income from Shanghai Pharmaceuticals, first-half net profit growth was 8.30 percent and second-quarter growth was 13.20 percent, according to Futunn.

What does the target imply?

The CNY 57.00 target lies 10.89 percent above the CNY 51.40 closing price on October 9, 2026. Investing.com listed 12 analyst ratings, including 11 Buy ratings and one Hold, with an average 12-month target of CNY 67.86.

Three dates define the story

On August 29, 2026, the latest quarterly release showed CNY 10.28 billion in revenue and CNY 1.66 billion in net income, according to Investing.com. On September 21, 2026, Yunnan Baiyao launched an X-series toothpaste in Bangkok with Thai partner Osotspa, as iMedia reported. On September 23, 2026, the analyst note cut its target to CNY 57.00 from CNY 65.78.

Stock valuation and overseas growth

The international expansion remains small relative to the group. Yunnan Baiyao's overseas revenue was CNY 109.00 million in fiscal year 2025, equal to 0.26 percent of total revenue, while first-half 2026 health-products revenue reached CNY 3.45 billion and net profit was CNY 740.00 million, according to iMedia.

Yunnan Baiyao closed at CNY 51.40 on the Shenzhen Stock Exchange on October 9, 2026. The finance snapshot showed a CNY 94.7 billion market capitalization and a CNY 46.29 to CNY 58.20 52-week range as of October 16, 2026.